NEULAND LABORATORIES
Back to Balance Sheet
|
NEULAND LABORATORIES Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹8.97 Cr | ₹28 Cr | ₹91 Cr | ₹75 Cr | ₹105 Cr |
What is the latest Contingent Liabilities ratio of NEULAND LABORATORIES ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹8.97 Cr |
| Mar2024 | ₹28 Cr |
| Mar2023 | ₹91 Cr |
| Mar2022 | ₹75 Cr |
| Mar2021 | ₹105 Cr |
How is Contingent Liabilities of NEULAND LABORATORIES Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹8.97 Cr | -67.65 | |
| Mar2024 | ₹28 Cr | -69.60 | |
| Mar2023 | ₹91 Cr | 22.14 | |
| Mar2022 | ₹75 Cr | -28.68 | |
| Mar2021 | ₹105 Cr | - | |
Compare Contingent Liabilities of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹19,540.0 Cr | 2.2% | -10.1% | 10.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹414,929.0 Cr | 0.7% | -4.2% | -8.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹169,644.0 Cr | 0% | -1% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹131,481.0 Cr | 2.4% | 4.5% | 14.5% | Stock Analytics | |
| CIPLA | ₹122,050.0 Cr | 1.1% | 0.2% | -1.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,784.0 Cr | -1% | -2% | -9.7% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 2.2% |
-10.1% |
10.1% |
| SENSEX | 0.9% |
0.7% |
9.6% |
You may also like the below Video Courses